BioNTech stock target raised on promising drug data

Sep 16, 2024 · BioNTech stock target raised on promising drug data. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of ...

$91
OFF

Jefferies Upgrades BioNTech Stock On Promising Cancer Drug …

2 weeks from now

Sep 17, 2024 · JPMorgan upgraded BioNTech's stock from Underweight to Neutral, raising the price target from $91 to $125, based on promising data from the company's phase II and …

investing.com

7%
OFF

Jefferies Lifts BioNTech Stock Price Target On New Drug Potential

2 weeks from now

Sep 13, 2024 · According to InvestingPro data, BioNTech's market capitalization stands at a robust $24.97 billion, despite a notable revenue decline of 70.7% over the last twelve months …

investing.com

$171.00
OFF

Promising BNT327 Data Bolsters BioNTech’s Buy Rating, With A …

2 weeks from now

Sep 10, 2024 · Analyst John Newman of Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), retaining the price target of $171.00.. John …

businessinsider.com

$150
OFF

BioNTech Stock Raised To Buy At Jefferies (NASDAQ:BNTX)

2 weeks from now

Sep 17, 2024 · Tewari raised his price target on BNTX to $150 from $96 as he projected €3.6B in risk-adjusted peak sales for BNT327. More on BioNTech BioNTech's Low Valuation, Many …

seekingalpha.com

$140.76
OFF

BioNTech (BNTX) Stock Forecast And Price Target 2025 - MarketBeat

2 weeks from now

6 days ago · BioNTech SE has received multiple upgrades from analysts, with a current average price target of $140.76, suggesting that analysts are optimistic about the company's future …

marketbeat.com

$102.38
OFF

Forecasting The Future: 8 Analyst Projections For BioNTech

2 weeks from now

Sep 13, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $102.38, a high estimate of $113.00, and a low …

nasdaq.com

15%
OFF

Breaking Down BioNTech: 16 Analysts Share Their Views

2 weeks from now

Nov 6, 2024 · This current average reflects an increase of 18.15% from the previous average price target of $107.44. ... value of BioNTech's stock. This comparison reveals trends in …

nasdaq.com

$121.33
OFF

Forecasting The Future: 15 Analyst Projections For BioNTech

2 weeks from now

Oct 7, 2024 · Analysts have set 12-month price targets for BioNTech, revealing an average target of $121.33, a high estimate of $150.00, and a low estimate of $85.00. ... future value of …

nasdaq.com

$171.00
OFF

BioNTech SE: A Strong Buy On BNT327’s Promising Cancer …

2 weeks from now

Sep 17, 2024 · In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $171.00. John …

businessinsider.com

$171.44
OFF

BioNTech SE’s Promising Future: Buy Rating Backed By …

2 weeks from now

Dec 11, 2024 · BioNTech price target raised to $171.44 from $171 at Canaccord BioNTech price target lowered to $122 from $124 at JPMorgan Trump Trade: Trump Media considers …

businessinsider.com

40%
OFF

This Biotech Stock Is An 'oncology Powerhouse' With 40% Upside, …

2 weeks from now

5 days ago · The firm's 12-month price target on the Nasdaq-traded shares of the German company is $172.

cnbc.com

$171.44
OFF

BioNTech Price Target Raised To $171.44 From $171 At Canaccord

2 weeks from now

Nov 27, 2024 · Canaccord analyst William Maughan raised the firm’s price target on BioNTech (BNTX) to $171.44 from $171 and keeps a Buy rating on the shares. The firm said there are …

nasdaq.com

40%
OFF

Truist Rates BioNTech A Buy, Citing 40% Upside ... - Investing.com

2 weeks from now

6 days ago · On Friday, Truist Securities began coverage on BioNTech shares (NASDAQ: BNTX) with a Buy rating, accompanied by a price target set at $172.00.The securities firm's analysis …

investing.com

$132
OFF

TD Cowen Maintains Hold Rating On BioNTech Stock With Raised …

2 weeks from now

Oct 21, 2024 · TD Cowen has maintained a Hold rating on BioNTech (NASDAQ: NASDAQ: BNTX), while increasing the stock's price target to $132 from $85. The adjustment reflects an …

investing.com

$150.00
OFF

Bank Of America Securities Keeps Their Buy Rating On BioNTech SE …

2 weeks from now

1 day ago · Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of $150.00. The …

businessinsider.com

94%
OFF

Moderna Stock Has Lost 94% Of Its Value Over Four Years. Is It A …

2 weeks from now

1 day ago · Moderna stock peaked at 497.49 in August 2021, at the height of the Covid pandemic. Since then, the stock has fallen precipitously, down 94% over the past four years. Is Moderna …

investors.com

$196.00
OFF

Derek Archila’s Buy Rating On Ascendis Pharma Backed By …

2 weeks from now

3 days ago · Derek Archila’s Buy Rating on Ascendis Pharma Backed by Promising Yorvipath Launch and Growth Potential ... a Buy rating on the stock with a $196.00 price target. ... price …

businessinsider.com

FAQs about BioNTech stock target raised on promising drug data Coupon?

Why did biontech stock trade higher on Tuesday?

BioNTech (NASDAQ: BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from Hold, citing the potential of a new cancer drug it is developing with its Chinese partner Biotheus. ...

Should you buy biontech se (bntx)?

Analyst John Newman of Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), retaining the price target of $171.00. John Newman’s rating is based on the promising data from Summit’s ivonescimab, which he believes offers a positive read-through to BioNTech’s BNT327 program. ...

What is the average price target for biontech (bntx)?

According to the 14 analysts' twelve-month price targets for BioNTech, the average price target is $135.54. The highest price target for BNTX is $171.00, while the lowest price target for BNTX is $100.00. The average price target represents a forecasted upside of 22.24% from the current price of $110.88. ...

Is biontech a good stock to buy in 2025?

With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds. In November, BioNTech agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases. ...

Why did Mohit Bansal buy biontech se?

Mohit Bansal has given his Buy rating due to a combination of factors that highlight BioNTech SE’s promising future prospects. One of the primary reasons is the promising early trial results of BNT327, a bispecific PD1/VEGF therapy, which has shown superior efficacy compared to existing treatments in various cancer settings. ...

Should you buy biontech se (AHM)?

According to TipRanks, Ahmad has an average return of 0.8% and a 47.97% success rate on recommended stocks. Currently, the analyst consensus on BioNTech SE is a Strong Buy with an average price target of $143.99, implying a 28.07% upside from current levels. ...